Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | MOGAT2 | Q3SYC2 | 6/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | TEK | Q02763 | 2/20 | 0.38 |
| ▸ | RAF1 | P04049 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5426991 | 0.83 | KDR (0.42) | BRAFCYP3A4MOGAT2KDR | |
| SCHEMBL545528 | 0.81 | MOGAT2 (0.41) | BRAFCYP3A4MOGAT2KDR | |
| SCHEMBL545055 | 0.79 | RAF1 (0.45) | BRAFCYP3A4KDRRAF1 | |
| SCHEMBL545003 | 0.78 | ABL1 (0.47) | BRAFMOGAT2KDRTEKRAF1 | |
| SCHEMBL545651 | 0.75 | BRAF (0.46) | BRAFCYP3A4KDRRAF1 | |
| SCHEMBL545184 | 0.73 | BRAF (0.45) | BRAFCYP3A4KDRRAF1 | |
| SCHEMBL545164 | 0.71 | RAF1 (0.56) | BRAFKDRRAF1 | |
| SCHEMBL5417651 | 0.71 | BRAF (0.54) | BRAFCYP3A4KDRRAF1 | |
| SCHEMBL5416318 | 0.70 | NFKB1 (0.46) | BRAFKDRRAF1 | |
| SCHEMBL14493433 | 0.69 | RAF1 (0.54) | BRAFKDRRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | BRAF 215/4885CYP3A4 3260/4885MOGAT2 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.